Inclusion Criteria:

          -  Participants who are intolerant or resistant to standard treatment for selected solid
             tumors

          -  at least one measurable or non-measurable lesion, not previously irradiated, as
             defined by RECIST 1.1

          -  ECOG Performance Status 0 or 1, 2 with approval

          -  Adequate Bone Marrow Function

          -  Adequate Renal Function

          -  Adequate Liver Function

          -  Resolved acute effects of any prior therapy

        Exclusion Criteria:

          -  Known active uncontrolled or symptomatic CNS metastases

          -  Major surgery within 6 weeks, radiation therapy within 4 weeks, systemic anti-cancer
             therapy within 2 week or 5 half-lives (4 weeks or 5 half-lives for antibody therapies
             or investigational drug(s) taken on another study) prior to study entry

          -  Active or history of autoimmune disease requiring >10mg/day prednisone or other
             concurrent immunosuppressive therapy

          -  Active, uncontrolled infection (controlled HBV, HCV, HIV/AIDS may be allowed) as
             defined in protocol

          -  Retinal or other serious ophthalmic disorders as defined in protocol

          -  Clinically significant cardiac disease as defined in protocol

          -  Inability to consume or absorb study drug

          -  Known or suspected hypersensitivity to PF-07265807

          -  Prohibited concomitant medications as defined in protocol